» Articles » PMID: 2891533

Flosequinan As a Third Agent for the Treatment of Hypertension: a Placebo Controlled, Double-blind Study

Overview
Specialty Pharmacology
Date 1987 Jan 1
PMID 2891533
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The acute and short term antihypertensive effect of flosequinan was determined in 16 hypertensive patients whose blood pressure was inadequately controlled despite treatment with a beta-adrenoceptor blocking agent and a diuretic. Erect and supine systolic and diastolic blood pressure was significantly reduced by flosequinan over the treatment period as compared to placebo. Heart rate was unchanged by flosequinan. Adverse effects were limited to mild headache in 3 patients and taste disturbance in 1 patient, possibly due to salivary excretion of the drug. Flosequinan is a potentially useful vasodilator for the treatment of hypertension.

Citing Articles

Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects.

Ng H, Walley T, Tsao Y, Breckenridge A Eur J Clin Pharmacol. 1994; 46(4):361-5.

PMID: 7957523 DOI: 10.1007/BF00194406.


Flosequinan for congestive heart failure: what promise does it hold?.

Hampton J Cardiovasc Drugs Ther. 1990; 4(5):1313-5.

PMID: 2278865 DOI: 10.1007/BF02018256.


The effects of flosequinan on regional blood flow in normal man.

Scott R, Woods K, Barnett D Br J Clin Pharmacol. 1991; 31(1):41-6.

PMID: 2015169 PMC: 1368410. DOI: 10.1111/j.1365-2125.1991.tb03855.x.


Flosequinan, a vasodilator with a novel mechanism of action.

Resnick M, Maitland L, Morgan K Br J Pharmacol. 1991; 102(4):974-8.

PMID: 1855126 PMC: 1917979. DOI: 10.1111/j.1476-5381.1991.tb12286.x.


Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers.

Duranteau J, Pussard E, Edouard A, Samii K, Berdeaux A, Giudicelli J Br J Clin Pharmacol. 1992; 34(3):207-14.

PMID: 1389945 PMC: 1381390. DOI: 10.1111/j.1365-2125.1992.tb04126.x.

References
1.
Wynne R, Crampton E, Hind I . The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers. Eur J Clin Pharmacol. 1985; 28(6):659-64. DOI: 10.1007/BF00607911. View

2.
Cowley A, Wynne R, Hampton J . The effects of BTS 49465 on blood pressure and peripheral arteriolar and venous tone in normal volunteers. J Hypertens Suppl. 1984; 2(3):S547-9. View